Low molecular weight heparin in prevention of perioperative thrombosis.
PDF (1.7M)
Journal: 1993/January - BMJ (Clinical research ed.)
ISSN: 0959-8138
PUBMED: 1281030
Abstract:
OBJECTIVE
To determine whether prophylactic treatment with low molecular weight heparin reduces the incidence of thrombosis in patients who have had general or orthopaedic surgery.
METHODS
Meta-analysis of results from 52 randomised, controlled clinical studies (29 in general surgery and 23 in orthopaedic surgery) in which low molecular weight heparin was compared with placebo, dextran, or unfractionated heparin.
METHODS
Patients who had had general or orthopaedic surgery.
METHODS
Once daily injection of a low molecular weight heparin compared with placebo, dextran, or unfractionated heparin.
METHODS
Incidence of deep venous thrombosis, pulmonary embolism, major haemorrhages, and death.
RESULTS
The results confirm that low molecular weight heparins are more efficacious for the prophylactic treatment of deep venous thrombosis than placebo (common odds ratio 0.31, 95% confidence interval 0.22 to 0.43; p < 0.001) and dextran (0.44, 0.30 to 0.65; p < 0.001). The results suggest that low molecular weight heparins are also more efficacious than unfractionated heparin (0.85, 0.74 to 0.97; p = 0.02), with no significant difference in the incidence of major haemorrhages (1.06, 0.93 to 1.20; p = 0.62).
CONCLUSIONS
Low molecular weight heparins seem to have a higher benefit to risk ratio than unfractionated heparin in preventing perioperative thrombosis. However, it remains to be shown in a suitably powered clinical trial whether low molecular weight heparin reduces the risk of fatal pulmonary embolism compared with heparin.
Open in
PUBMED | PMC | Google Scholar | Wikipedia
Relations:
Content
Citations
(41)
References
(59)
Diseases
(2)
Conditions
(2)
Chemicals
(4)
Organisms
(1)
Affiliates
(1)
Similar articles
Articles by the same authors
Discussion board
BMJ 305(6859): 913-920
PMID: 1281030

Low molecular weight heparin in prevention of perioperative thrombosis.

Abstract

OBJECTIVE--To determine whether prophylactic treatment with low molecular weight heparin reduces the incidence of thrombosis in patients who have had general or orthopaedic surgery. DESIGN--Meta-analysis of results from 52 randomised, controlled clinical studies (29 in general surgery and 23 in orthopaedic surgery) in which low molecular weight heparin was compared with placebo, dextran, or unfractionated heparin. SUBJECTS--Patients who had had general or orthopaedic surgery. INTERVENTION--Once daily injection of a low molecular weight heparin compared with placebo, dextran, or unfractionated heparin. MAIN OUTCOME MEASURES--Incidence of deep venous thrombosis, pulmonary embolism, major haemorrhages, and death. RESULTS--The results confirm that low molecular weight heparins are more efficacious for the prophylactic treatment of deep venous thrombosis than placebo (common odds ratio 0.31, 95% confidence interval 0.22 to 0.43; p < 0.001) and dextran (0.44, 0.30 to 0.65; p < 0.001). The results suggest that low molecular weight heparins are also more efficacious than unfractionated heparin (0.85, 0.74 to 0.97; p = 0.02), with no significant difference in the incidence of major haemorrhages (1.06, 0.93 to 1.20; p = 0.62). CONCLUSIONS--Low molecular weight heparins seem to have a higher benefit to risk ratio than unfractionated heparin in preventing perioperative thrombosis. However, it remains to be shown in a suitably powered clinical trial whether low molecular weight heparin reduces the risk of fatal pulmonary embolism compared with heparin.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.7M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.
icon of scanned page 913
913
icon of scanned page 914
914
icon of scanned page 915
915
icon of scanned page 916
916
icon of scanned page 917
917
icon of scanned page 918
918
icon of scanned page 919
919
icon of scanned page 920
920

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Lieberman J, Winter B, Sastre A. Alpha 1-antitrypsin Pi-types in 965 COPD patients. Chest. 1986 Mar;89(3):370–373. [PubMed] [Google Scholar]
  • Cicero R, del Vecchyo C, Porter JK, Carreño J. Open window thoracostomy and plastic surgery with muscle flaps in the treatment of chronic empyema. Chest. 1986 Mar;89(3):374–377. [PubMed] [Google Scholar]
  • Kakkar VV. Prevention of venous thromboembolism. Clin Haematol. 1981 Jun;10(2):543–582. [PubMed] [Google Scholar]
  • Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med. 1988 May 5;318(18):1162–1173. [PubMed] [Google Scholar]
  • Bergqvist D. Dextran in the prophylaxis of deep-vein thrombosis. JAMA. 1987 Jul 17;258(3):324–325. [PubMed] [Google Scholar]
  • Hirsh J. From unfractionated heparins to low molecular weight heparins. Acta Chir Scand Suppl. 1990;556:42–50. [PubMed] [Google Scholar]
  • Carter CJ, Kelton JG, Hirsh J, Cerskus A, Santos AV, Gent M. The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits. Blood. 1982 Jun;59(6):1239–1245. [PubMed] [Google Scholar]
  • Cade JF, Buchanan MR, Boneu B, Ockelford P, Cater CJ, Cerskus AL, Hirsh J. A comparison of the antithrombotic and haemorrhagic effects of low molecular weight heparin fractions: the influence of the method of preparation. Thromb Res. 1984 Sep 15;35(6):613–625. [PubMed] [Google Scholar]
  • Buchanan MR, Boneu B, Ofosu F, Hirsh J. The relative importance of thrombin inhibition and factor Xa inhibition to the antithrombotic effects of heparin. Blood. 1985 Jan;65(1):198–201. [PubMed] [Google Scholar]
  • Esquivel CO, Bergqvist D, Björck CG, Nilsson B. Comparison between commercial heparin, low molecular weight heparin and pentosan polysulfate on hemostasis and platelets in vivo. Thromb Res. 1982 Nov 1;28(3):389–399. [PubMed] [Google Scholar]
  • Lane DA, Denton J, Flynn AM, Thunberg L, Lindahl U. Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4. Biochem J. 1984 Mar 15;218(3):725–732.[PMC free article] [PubMed] [Google Scholar]
  • Lockner D, Bratt G, Törnebohm E, Aberg W. Pharmacokinetics of intravenously and subcutaneously administered Fragmin in healthy volunteers. Haemostasis. 1986;16 (Suppl 2):8–10. [PubMed] [Google Scholar]
  • Frydman AM, Bara L, Le Roux Y, Woler M, Chauliac F, Samama MM. The antithrombotic activity and pharmacokinetics of enoxaparine, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 mg. J Clin Pharmacol. 1988 Jul;28(7):609–618. [PubMed] [Google Scholar]
  • Boissel JP, Bossard N. Registry of multicenter clinical trials. Eleventh report--1989. Thromb Haemost. 1991 Sep 2;66(3):368–383. [PubMed] [Google Scholar]
  • Boissel JP, Sacks HS, Leizorovicz A, Blanchard J, Panak E, Peyrieux JC. Meta-analysis of clinical trials: summary of an international conference. Eur J Clin Pharmacol. 1988;34(6):535–538. [PubMed] [Google Scholar]
  • Thompson SG, Pocock SJ. Can meta-analyses be trusted? Lancet. 1991 Nov 2;338(8775):1127–1130. [PubMed] [Google Scholar]
  • Ockelford PA, Patterson J, Johns AS. A double-blind randomized placebo controlled trial of thromboprophylaxis in major elective general surgery using once daily injections of a low molecular weight heparin fragment (Fragmin). Thromb Haemost. 1989 Dec 29;62(4):1046–1049. [PubMed] [Google Scholar]
  • Valle I, Sola G, Origone A. Controlled clinical study of the efficacy of a new low molecular weight heparin administered subcutaneously to prevent post-operative deep venous thrombosis. Curr Med Res Opin. 1988;11(2):80–86. [PubMed] [Google Scholar]
  • Turpie AG, Levine MN, Hirsh J, Carter CJ, Jay RM, Powers PJ, Andrew M, Hull RD, Gent M. A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. N Engl J Med. 1986 Oct 9;315(15):925–929. [PubMed] [Google Scholar]
  • Tørholm C, Broeng L, Jørgensen PS, Bjerregaard P, Josephsen L, Jørgensen PK, Hagen K, Knudsen JB. Thromboprophylaxis by low-molecular-weight heparin in elective hip surgery. A placebo controlled study. J Bone Joint Surg Br. 1991 May;73(3):434–438. [PubMed] [Google Scholar]
  • Samama M, Bernard P, Bonnardot JP, Combe-Tamzali S, Lanson Y, Tissot E. Low molecular weight heparin compared with unfractionated heparin in prevention of postoperative thrombosis. Br J Surg. 1988 Feb;75(2):128–131. [PubMed] [Google Scholar]
  • Verardi S, Casciani CU, Nicora E, Forzano F, Origone A, Valle I, Catania G, Salanitri G, Salcuni P, Azzarone M, et al. A multicentre study on LMW-heparin effectiveness in preventing postsurgical thrombosis. Int Angiol. 1988 Jul-Sep;7(3 Suppl):19–24. [PubMed] [Google Scholar]
  • Bergqvist D, Burmark US, Frisell J, Hallbök T, Lindblad B, Risberg B, Törngren S, Wallin G. Low molecular weight heparin once daily compared with conventional low-dose heparin twice daily. A prospective double-blind multicentre trial on prevention of postoperative thrombosis. Br J Surg. 1986 Mar;73(3):204–208. [PubMed] [Google Scholar]
  • Koller M, Schoch U, Buchmann P, Largiadèr F, von Felten A, Frick PG. Low molecular weight heparin (KABI 2165) as thromboprophylaxis in elective visceral surgery. A randomized, double-blind study versus unfractionated heparin. Thromb Haemost. 1986 Dec 15;56(3):243–246. [PubMed] [Google Scholar]
  • Onarheim H, Lund T, Heimdal A, Arnesjø B. A low molecular weight heparin (KABI 2165) for prophylaxis of postoperative deep venous thrombosis. Acta Chir Scand. 1986 Oct;152:593–596. [PubMed] [Google Scholar]
  • Bergqvist D, Mätzsch T, Burmark US, Frisell J, Guilbaud O, Hallbök T, Horn A, Lindhagen A, Ljungnér H, Ljungström KG, et al. Low molecular weight heparin given the evening before surgery compared with conventional low-dose heparin in prevention of thrombosis. Br J Surg. 1988 Sep;75(9):888–891. [PubMed] [Google Scholar]
  • Borstad E, Urdal K, Handeland G, Abildgaard U. Comparison of low molecular weight heparin vs. unfractionated heparin in gynecological surgery. Acta Obstet Gynecol Scand. 1988;67(2):99–103. [PubMed] [Google Scholar]
  • Briel RC, Doller P, Hermann CP. Thromboembolie-Prophylaxe bei Hysterektomien mit dem niedermolekularen Heparin Fragmin. Geburtshilfe Frauenheilkd. 1988 Mar;48(3):160–164. [PubMed] [Google Scholar]
  • Caen JP. A randomized double-blind study between a low molecular weight heparin Kabi 2165 and standard heparin in the prevention of deep vein thrombosis in general surgery. A French multicenter trial. Thromb Haemost. 1988 Apr 8;59(2):216–220. [PubMed] [Google Scholar]
  • Fricker JP, Vergnes Y, Schach R, Heitz A, Eber M, Grunebaum L, Wiesel ML, Kher A, Barbier P, Cazenave JP. Low dose heparin versus low molecular weight heparin (Kabi 2165, Fragmin) in the prophylaxis of thromboembolic complications of abdominal oncological surgery. Eur J Clin Invest. 1988 Dec;18(6):561–567. [PubMed] [Google Scholar]
  • Hartl P, Brücke P, Dienstl E, Vinazzer H. Prophylaxis of thromboembolism in general surgery: comparison between standard heparin and Fragmin. Thromb Res. 1990 Feb 15;57(4):577–584. [PubMed] [Google Scholar]
  • Kakkar VV, Murray WJ. Efficacy and safety of low-molecular-weight heparin (CY216) in preventing postoperative venous thrombo-embolism: a co-operative study. Br J Surg. 1985 Oct;72(10):786–791. [PubMed] [Google Scholar]
  • Liezorovicz A, Picolet H, Peyrieux JC, Boissel JP. Prevention of perioperative deep vein thrombosis in general surgery: a multicentre double blind study comparing two doses of Logiparin and standard heparin. H.B.P.M. Research Group. Br J Surg. 1991 Apr;78(4):412–416. [PubMed] [Google Scholar]
  • Schmitz-Huebner U, Bünte H, Freise G, Reers B, Rüschemeyer C, Scherer R, Schulte H, van de Loo J. Clinical efficacy of low molecular weight heparin in postoperative thrombosis prophylaxis. Klin Wochenschr. 1984 Apr 16;62(8):349–353. [PubMed] [Google Scholar]
  • Adolf J, Knee H, Roder JD, van de Flierdt E, Siewert JR. Thromboembolieprophylaxe mit niedermolekularem Heparin in der Abdominalchirurgie. Dtsch Med Wochenschr. 1989 Jan 13;114(2):48–53. [PubMed] [Google Scholar]
  • Heilmann L, Kruck M, Schindler AE. Thromboseprophylaxe in der Gynäkologie: Doppelblind-Vergleich zwischen niedermolekularem (LMWH) und unfraktioniertem (UFH) Heparin. Geburtshilfe Frauenheilkd. 1989 Sep;49(9):803–807. [PubMed] [Google Scholar]
  • Sasahara AA, Koppenhagen K, Häring R, Welzel D, Wolf H. Low molecular weight heparin plus dihydroergotamine for prophylaxis of postoperative deep vein thrombosis. Br J Surg. 1986 Sep;73(9):697–700. [PubMed] [Google Scholar]
  • Baumgartner A, Jacot N, Moser G, Krähenbühl B. Prevention of postoperative deep vein thrombosis by one daily injection of low molecular weight heparin and dihydroergotamine. Vasa. 1989;18(2):152–156. [PubMed] [Google Scholar]
  • Kakkar VV, Stringer MD, Hedges AR, Parker CJ, Welzel D, Ward VP, Sanderson RM, Cooper D, Kakkar S. Fixed combinations of low-molecular weight or unfractionated heparin plus dihydroergotamine in the prevention of postoperative deep vein thrombosis. Am J Surg. 1989 Apr;157(4):413–418. [PubMed] [Google Scholar]
  • Planes A, Vochelle N, Mazas F, Mansat C, Zucman J, Landais A, Pascariello JC, Weill D, Butel J. Prevention of postoperative venous thrombosis: a randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement. Thromb Haemost. 1988 Dec 22;60(3):407–410. [PubMed] [Google Scholar]
  • Chiapuzzo E, Orengo GB, Ottria G, Chiapuzzo A, Palazzini E, Fusillo M. The use of low molecular weight heparins for postsurgical deep vein thrombosis prevention in orthopaedic patients. J Int Med Res. 1988 Sep-Oct;16(5):359–366. [PubMed] [Google Scholar]
  • Pini M, Tagliaferri A, Manotti C, Lasagni F, Rinaldi E, Dettori AG. Low molecular weight heparin (Alfa LHWH) compared with unfractionated heparin in prevention of deep-vein thrombosis after hip fractures. Int Angiol. 1989 Jul-Sep;8(3):134–139. [PubMed] [Google Scholar]
  • Dechavanne M, Ville D, Berruyer M, Trepo F, Dalery F, Clermont N, Lerat JL, Moyen B, Fischer LP, Kher A, et al. Randomized trial of a low-molecular-weight heparin (Kabi 2165) versus adjusted-dose subcutaneous standard heparin in the prophylaxis of deep-vein thrombosis after elective hip surgery. Haemostasis. 1989;19(1):5–12. [PubMed] [Google Scholar]
  • Monreal M, Lafoz E, Navarro A, Granero X, Caja V, Caceres E, Salvador R, Ruiz J. A prospective double-blind trial of a low molecular weight heparin once daily compared with conventional low-dose heparin three times daily to prevent pulmonary embolism and venous thrombosis in patients with hip fracture. J Trauma. 1989 Jun;29(6):873–875. [PubMed] [Google Scholar]
  • Leyvraz PF, Bachmann F, Hoek J, Büller HR, Postel M, Samama M, Vandenbroek MD. Prevention of deep vein thrombosis after hip replacement: randomised comparison between unfractionated heparin and low molecular weight heparin. BMJ. 1991 Sep 7;303(6802):543–548.[PMC free article] [PubMed] [Google Scholar]
  • Haas S, Stemberger A, Fritsche HM, Welzel D, Wolf H, Lechner F, Blümel G. Prophylaxis of deep vein thrombosis in high risk patients undergoing total hip replacement with low molecular weight heparin plus dihydroergotamine. Arzneimittelforschung. 1987 Jul;37(7):839–843. [PubMed] [Google Scholar]
  • Lassen MR, Borris LC, Christiansen HM, Møller-Larsen F, Knudsen VE, Boris P, Nehen AM, de Carvalho A, Jurik AG, Nielsen BW, et al. Heparin/dihydroergotamine for venous thrombosis prophylaxis: comparison of low-dose heparin and low molecular weight heparin in hip surgery. Br J Surg. 1988 Jul;75(7):686–689. [PubMed] [Google Scholar]
  • Lassen MR, Borris LC, Christiansen HM, Møller-Larsen F, Knudsen VE, Boris P, Nehen AM, Jurik AG, de Carvalho A, Nielsen BW, et al. Prevention of thromboembolism in hip-fracture patients. Comparison of low-dose heparin and low-molecular-weight heparin combined with dihydroergotamine. Arch Orthop Trauma Surg. 1989;108(1):10–13. [PubMed] [Google Scholar]
  • Eriksson BI, Zachrisson BE, Teger-Nilsson AC, Risberg B. Thrombosis prophylaxis with low molecular weight heparin in total hip replacement. Br J Surg. 1988 Nov;75(11):1053–1057. [PubMed] [Google Scholar]
  • Mätzsch T, Bergqvist D, Fredin H, Hedner U. Safety and efficacy of a low molecular weight heparin (Logiparin) versus dextran as prophylaxis against thrombosis after total hip replacement. Acta Chir Scand Suppl. 1988;543:80–84. [PubMed] [Google Scholar]
  • Hoffmann R, Largiadèr F, Roethlin M. Perioperative Thromboembolie-Prophylaxe: niedrig dosiertes Heparin oder low molecular Heparin-DHE, Vor- und Nachteile. Eine prospektive, randomisierte Untersuchung. Helv Chir Acta. 1987 Dec;54(4):521–525. [PubMed] [Google Scholar]
  • Collet JP, Boissel JP. Sick population--treated population: the need for a better definition. The VALIDATA Group. Eur J Clin Pharmacol. 1991;41(4):267–271. [PubMed] [Google Scholar]
  • Simes RJ. Confronting publication bias: a cohort design for meta-analysis. Stat Med. 1987 Jan-Feb;6(1):11–29. [PubMed] [Google Scholar]
  • Simes RJ. Publication bias: the case for an international registry of clinical trials. J Clin Oncol. 1986 Oct;4(10):1529–1541. [PubMed] [Google Scholar]
  • Dickersin K. Report from the panel on the Case for Registers of Clinical Trials at the Eighth Annual Meeting of the Society for Clinical Trials. Control Clin Trials. 1988 Mar;9(1):76–81. [PubMed] [Google Scholar]
  • Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet. 1991 Apr 13;337(8746):867–872. [PubMed] [Google Scholar]
  • Colditz GA, Tuden RL, Oster G. Rates of venous thrombosis after general surgery: combined results of randomised clinical trials. Lancet. 1986 Jul 19;2(8499):143–146. [PubMed] [Google Scholar]
  • Leyvraz PF, Richard J, Bachmann F, Van Melle G, Treyvaud JM, Livio JJ, Candardjis G. Adjusted versus fixed-dose subcutaneous heparin in the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med. 1983 Oct 20;309(16):954–958. [PubMed] [Google Scholar]
  • Taberner DA, Poller L, Thomson JM, Lemon G, Weighill FJ. Randomized study of adjusted versus fixed low dose heparin prophylaxis of deep vein thrombosis in hip surgery. Br J Surg. 1989 Sep;76(9):933–935. [PubMed] [Google Scholar]
Unité de Pharmacologie Clinique, Lyons, France.
Unité de Pharmacologie Clinique, Lyons, France.
Copyright notice
Abstract
OBJECTIVE--To determine whether prophylactic treatment with low molecular weight heparin reduces the incidence of thrombosis in patients who have had general or orthopaedic surgery. DESIGN--Meta-analysis of results from 52 randomised, controlled clinical studies (29 in general surgery and 23 in orthopaedic surgery) in which low molecular weight heparin was compared with placebo, dextran, or unfractionated heparin. SUBJECTS--Patients who had had general or orthopaedic surgery. INTERVENTION--Once daily injection of a low molecular weight heparin compared with placebo, dextran, or unfractionated heparin. MAIN OUTCOME MEASURES--Incidence of deep venous thrombosis, pulmonary embolism, major haemorrhages, and death. RESULTS--The results confirm that low molecular weight heparins are more efficacious for the prophylactic treatment of deep venous thrombosis than placebo (common odds ratio 0.31, 95% confidence interval 0.22 to 0.43; p < 0.001) and dextran (0.44, 0.30 to 0.65; p < 0.001). The results suggest that low molecular weight heparins are also more efficacious than unfractionated heparin (0.85, 0.74 to 0.97; p = 0.02), with no significant difference in the incidence of major haemorrhages (1.06, 0.93 to 1.20; p = 0.62). CONCLUSIONS--Low molecular weight heparins seem to have a higher benefit to risk ratio than unfractionated heparin in preventing perioperative thrombosis. However, it remains to be shown in a suitably powered clinical trial whether low molecular weight heparin reduces the risk of fatal pulmonary embolism compared with heparin.
Collaboration tool especially designed for Life Science professionals.Drag-and-drop any entity to your messages.